Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study
Morozova Ma, T. A. Lepilkina, G. Rupchev, et al.
CNS Spectrums (2013) Vol. 19, Iss. 4, pp. 316-323
Closed Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Therapeutic Targeting of Autophagy
Christina G. Towers, Andrew Thorburn
EBioMedicine (2016) Vol. 14, pp. 15-23
Open Access | Times Cited: 246
Dual Role of Autophagy in Diseases of the Central Nervous System
Tamara Bar-Yosef, Odeya Damri, Galila Agam
Frontiers in Cellular Neuroscience (2019) Vol. 13
Open Access | Times Cited: 114
Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders
Ramakrishna Nirogi, Pradeep Jayarajan, Anil Shinde, et al.
Biomolecules (2023) Vol. 13, Iss. 2, pp. 309-309
Open Access | Times Cited: 29
Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds
Letizia Biso, Marco Carli, Marco Scarselli, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 85-85
Open Access | Times Cited: 1
Quinoline- and Isoquinoline-Sulfonamide Analogs of Aripiprazole: Novel Antipsychotic Agents?
Paweł Zajdel, Anna Partyka, Krzysztof Marciniec, et al.
Future Medicinal Chemistry (2013) Vol. 6, Iss. 1, pp. 57-75
Closed Access | Times Cited: 82
Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis
Igne Sinkeviciute, Marieke J.H. Begemann, Merel Prikken, et al.
Schizophrenia (2018) Vol. 4, Iss. 1
Open Access | Times Cited: 79
Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PET
Rajiv Radhakrishnan, Nabeel Nabulsi, Edward Gaiser, et al.
Journal of Nuclear Medicine (2018) Vol. 59, Iss. 9, pp. 1445-1450
Open Access | Times Cited: 55
Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments
Antón L. Martínez, José Brea, Sara Rico, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 9905-9905
Open Access | Times Cited: 34
Emerging drugs for schizophrenia: an update
Luisa-Sophie Köster, Maren Carbon, Christoph U. Correll
Expert Opinion on Emerging Drugs (2014) Vol. 19, Iss. 4, pp. 511-531
Closed Access | Times Cited: 49
Potential serotonergic agents for the treatment of schizophrenia
Ricardo P. Garay, Michel Bourin, Evelyne de Paillette, et al.
Expert Opinion on Investigational Drugs (2015) Vol. 25, Iss. 2, pp. 159-170
Closed Access | Times Cited: 39
In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET
Rajiv Radhakrishnan, David Matuskey, Nabeel Nabulsi, et al.
Psychiatry Research Neuroimaging (2019) Vol. 295, pp. 111007-111007
Closed Access | Times Cited: 31
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia
Tanja Veselinović, Irene Neuner
CNS Drugs (2022) Vol. 36, Iss. 8, pp. 819-858
Open Access | Times Cited: 17
AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer’s Disease
Alexandre V. Ivachtchenko, Yan Lavrovsky, Yan A. Ivanenkov
Molecular Pharmaceutics (2016) Vol. 13, Iss. 3, pp. 945-963
Closed Access | Times Cited: 30
A dual-acting 5-HT6 receptor inverse agonist/MAO-B inhibitor displays glioprotective and pro-cognitive properties
Vittorio Canale, Katarzyna Grychowska, Rafał Kurczab, et al.
European Journal of Medicinal Chemistry (2020) Vol. 208, pp. 112765-112765
Open Access | Times Cited: 22
The selective 5-HT 6 receptor antagonist SLV has putative cognitive- and social interaction enhancing properties in rodent models of cognitive impairment
Natasja de Bruin, Arnold van Loevezijn, Karsten Wicke, et al.
Neurobiology of Learning and Memory (2016) Vol. 133, pp. 100-117
Closed Access | Times Cited: 22
2-Aminoimidazole-based antagonists of the 5-HT6 receptor – A new concept in aminergic GPCR ligand design
Adam S. Hogendorf, Agata Hogendorf, Rafał Kurczab, et al.
European Journal of Medicinal Chemistry (2019) Vol. 179, pp. 1-15
Closed Access | Times Cited: 21
Existing and emerging pharmacological approaches to the treatment of mania: A critical overview
Giulio Sparacino, Norma Verdolini, Eduard Vieta, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 10
Pharmacotherapy of cognitive deficits in schizophrenia
Lewis A. Opler, Alice Medalia, Mark Opler, et al.
CNS Spectrums (2013) Vol. 19, Iss. 2, pp. 142-156
Closed Access | Times Cited: 17
5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schizophrenia
Morozova Ma, D. S. Burminskiy, George E. Rupchev, et al.
Journal of Clinical Psychopharmacology (2017) Vol. 37, Iss. 2, pp. 169-175
Closed Access | Times Cited: 16
Sulfonyl-containing modulators of serotonin 5-HT6receptors and their pharmacophore models
Alexandre V. Ivachtchenko
Russian Chemical Reviews (2014) Vol. 83, Iss. 5, pp. 439-473
Closed Access | Times Cited: 14
The blockade of the serotoninergic receptors 5-HT5A, 5-HT6 and 5-HT7 in the basolateral amygdala, but not in the hippocampus facilitate the extinction of fear memory
Eduardo Silva de Assis Brasil, Cristiane Regina Guerino Furini, Fernanda da Silva Rodrigues, et al.
Behavioural Brain Research (2019) Vol. 372, pp. 112055-112055
Closed Access | Times Cited: 14
<p>Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia</p>
Etsay Weldekidan Tsegay, Desalegn Getnet Demise, Nigus Alemu Hailu, et al.
Neuropsychiatric Disease and Treatment (2020) Vol. Volume 16, pp. 2499-2509
Open Access | Times Cited: 13
The impact of genetics on future drug discovery in schizophrenia
Mitsuyuki Matsumoto, Noah M. Walton, Hiroshi Yamada, et al.
Expert Opinion on Drug Discovery (2017) Vol. 12, Iss. 7, pp. 673-686
Closed Access | Times Cited: 13
Arylpiperazinylalkyl derivatives of 8-amino-1,3-dimethylpurine-2,6-dione as novel multitarget 5-HT/D receptor agents with potential antipsychotic activity
Grażyna Chłoń‐Rzepa, Adam Bucki, Marcin Kołaczkowski, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2015) Vol. 31, Iss. 6, pp. 1048-1062
Open Access | Times Cited: 12
Experimental Serotonergic Agents for the Treatment of Schizophrenia
Enrico Capuzzi, Alice Caldiroli, Veronica Ciscato, et al.
Journal of Experimental Pharmacology (2021) Vol. Volume 13, pp. 49-67
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top